Evidence map›Paper›PMID 36172374›Full record

ArticleFrontiers in immunology2022

Identification of ST3GAL5 as a prognostic biomarker correlating with CD8

Jiakuan Liu, Meiqian Li, Jiajun Wu, Qi Qi, Yang Li, Simei Wang, Shengjie Liang, Yuqing Zhang, Zhitao Zhu, Ruimin Huang and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Sialylation-immune-related lncRNAFrontiers in immunology · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Exosomes secreted by ST3GAL5Molecular oncology · 2024
    Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Jiakuan LiuDepartment of Urology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China.
Meiqian LiDepartment of Urology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China.
Jiajun WuDepartment of Laboratory Animal Science, Fudan University, Shanghai, China.
Qi QiDepartment of Laboratory Animal Science, Fudan University, Shanghai, China.
Yang LiDepartment of Urology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China.
Simei WangShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Shengjie LiangDepartment of Urology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China.
Yuqing ZhangDepartment of Urology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China.
Zhitao ZhuDepartment of Laboratory Animal Science, Fudan University, Shanghai, China.
Ruimin HuangShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Jun YanDepartment of Urology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China.
Rujian ZhuDepartment of Urology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China.
Fudan University · CNPudong Medical Center · CNChinese Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aberrant sialylation is frequently observed in tumor development, but which sialyltransferases are involved in this event are not well known. Herein, we performed comprehensive analyses on six ST3GAL family members, the α-2,3 sialyltransferases, in clear cell renal cell carcinoma (ccRCC) from public datasets. Only ST3GAL5 was consistently and significantly overexpressed in ccRCC (n = 791 in total), compared with normal kidney tissues. Its overexpression was positively correlated with tumor stage, grade, and the poor prognosis in ccRCC patients. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses indicated the involvement of ST3GAL5 in tumor immunoregulation. Then we revealed that ST3GAL5 expression showed a positive correlation with CD8

Indexed as

Carcinoma, Renal CellCD8-Positive T-LymphocytesKidney NeoplasmsSialyltransferasesBiomarkers, TumorHumansPrognosisBiomarkers, Tumorhaematoside synthetaseSialyltransferasesCD8+ T cell exhaustionclear cell renal cell carcinomaprognostic biomarkersialylationST3GAL5

Identifiers

PMID36172374
PMCPMC9510991
OpenAlexW4295233240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.